About this trial
This prospective, randomized, open-label, multicenter study is designed to evaluate the impact of an enhanced recovery after surgery (ERAS) protocol on the rate of meeting discharge criteria in patients undergoing minimally-invasive gastrectomy for gastric cancer. We hypothesize that implementation of our ERAS protocol will significantly increase the proportion of patients who meet standardized discharge criteria following minimally-invasive gastrectomy.
Eligibility criteria
Qualifiers
Adults aged ≥19 years scheduled to undergo elective laparoscopic or robotic gastrectomy for gastric cancer
American Society of Anesthesiologists physical status classification I to III
Ability to provide written informed consent, demonstrate understanding of the study protocol, and complete patient-reported outcome measures appropriately
Disqualifiers
Requirement for resection of organs other than the stomach during surgery (except for cholecystectomy)
History of upper abdominal surgery (except for cholecystectomy)
Known hypersensitivity to fentanyl, ropivacaine, acetaminophen, or non-steroidal anti-inflammatory drugs
Determined by the investigator or study personnel to be otherwise unsuitable for participation in the study
Trial design
Treatments tested in this trial
- ERAS protocol
Treatment groups
Sponsors and collaborators
Seoul National University Hospital
Lead sponsor
Seoul National University Bundang Hospital
Collaborator
Seoul National University Boramae Hospital
Collaborator
Severance Hospital
Collaborator
Chungnam National University Hospital
Collaborator
Keimyung University Dongsan Medical Center
Collaborator
National Cancer Center, Korea
Collaborator
The Catholic University of Korea
Collaborator
Ajou University School of Medicine
Collaborator
Pusan National University Hospital
Collaborator